AR040969A1 - Composiciones farmaceuticas de farmacos semiordenados y polimeros - Google Patents

Composiciones farmaceuticas de farmacos semiordenados y polimeros

Info

Publication number
AR040969A1
AR040969A1 ARP030102902A ARP030102902A AR040969A1 AR 040969 A1 AR040969 A1 AR 040969A1 AR P030102902 A ARP030102902 A AR P030102902A AR P030102902 A ARP030102902 A AR P030102902A AR 040969 A1 AR040969 A1 AR 040969A1
Authority
AR
Argentina
Prior art keywords
drug
composition
control composition
low solubility
concentration
Prior art date
Application number
ARP030102902A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31715934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR040969(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR040969A1 publication Critical patent/AR040969A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una composición caracterizada porque comprende: a) un sólido que comprende un fármaco de baja solubilidad y un polímero potenciador de la concentración; b) estando presente el citado polímero potenciador de la concentración en la citada composición en una cantidad suficiente para que la citada composición proporcione una concentración potenciada del citado fármaco de baja solubilidad en un entorno de uso respecto a una primera composición de control constituida esencialmente por una mezcla de una cantidad equivalente del citado fármaco en forma cristalina y una cantidad equivalente del citado polímero potenciador de la concentración; y c) en la que al menos una porción del citado fármaco está presente en regiones ricas en fármaco, y las citadas regiones ricas en fármaco están intercaladas a lo largo de regiones pobres en fármaco ricas en polímero, y en la que al menos un 20% en peso del citado fármaco de baja solubilidad está en un estado semiordenado. Reivindicación 3: La composición de la reivindicación 1, caracterizado porque el citado fármaco en el citado estado semiordenado exhibe al menos uno de: a) un patrón de difracción de rayos X en polvo que es diferente del patrón e rayos X en polvo de la citada primera composición de control, en el que al menos un pico presente en el citado patrón de difracción de la citada primera composición de control no está presente en el citado patrón de difracción del citado fármaco en la citada composición; b) un patrón de difracción de rayos X en polvo que tiene al menos un pico que tiene una anchura total a mitad de altura de al menos 1,1 veces la de un pico equivalente exhibido por el citado fármaco en la citada primera composición de control; c) una temperatura de transición vítrea que es diferente de la temperatura de transición vítrea de la citada segunda composición e control; estando constituida esencialmente la citada segunda composición de control por una dispersión sólida amorfa de una cantidad equivalente del citado fármaco y una cantidad equivalente del citado polímero potenciador de la concentración, siendo el citado fármaco en la citada segunda composición de control al menos un 90 % en peso amorfo; y d) un inicio o máximo de la endotermia de fusión que está a una temperatura inferior al inicio o máximo de la endotermia de la mezcla fundida del citado fármaco en la citada primera< composición de control. Reivindicación 9: Un proceso para formar una composición de control caracterizado porque comprende: a) formar una dispersión amorfa que comprende un fármaco de baja solubilidad y un polímero potenciador de la concentración; b) tratar la citada dispersión amorfa para aumentar la movilidad del citado fármaco en la citada dispersión amorfa mediante al menos uno de (1) calentar la citada dispersión y (2) exponer la citada dispersión a un agente potenciador de la movilidad; y c) convertir al menos un 20 % en peso del citado fármaco de baja solubilidad a un estado semiordenado.
ARP030102902A 2002-08-12 2003-08-11 Composiciones farmaceuticas de farmacos semiordenados y polimeros AR040969A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40308702P 2002-08-12 2002-08-12

Publications (1)

Publication Number Publication Date
AR040969A1 true AR040969A1 (es) 2005-04-27

Family

ID=31715934

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102902A AR040969A1 (es) 2002-08-12 2003-08-11 Composiciones farmaceuticas de farmacos semiordenados y polimeros

Country Status (24)

Country Link
US (2) US8257739B2 (es)
EP (2) EP2111856A3 (es)
JP (1) JP2006500349A (es)
CN (1) CN1681479A (es)
AR (1) AR040969A1 (es)
AT (1) ATE442130T1 (es)
AU (1) AU2003249474A1 (es)
BR (1) BR0313428A (es)
CA (1) CA2496441C (es)
DE (1) DE60329188D1 (es)
ES (1) ES2333318T3 (es)
GT (1) GT200300170A (es)
IL (1) IL166411A0 (es)
MX (1) MXPA05000977A (es)
NO (1) NO20050419L (es)
PA (1) PA8579801A1 (es)
PE (1) PE20040865A1 (es)
PL (1) PL375345A1 (es)
PT (1) PT1530457E (es)
RU (1) RU2005103625A (es)
TW (1) TW200406224A (es)
UY (1) UY27929A1 (es)
WO (1) WO2004014342A1 (es)
ZA (1) ZA200500470B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE60233874D1 (de) * 2001-06-22 2009-11-12 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CA2577852A1 (en) 2004-08-31 2006-03-09 Pfizer Products Inc. Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
CA2594694A1 (en) 2005-01-28 2006-08-03 Pfizer Products Inc. Drying of drug-containing particles
US8834929B2 (en) 2006-07-21 2014-09-16 Bend Research, Inc. Drying of drug-containing particles
EP2140883B1 (en) * 2007-04-20 2012-10-31 Daido Chemical Corporation Novel base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP3023433A1 (en) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
EP2654726A4 (en) 2011-03-08 2013-10-30 Zalicus Pharmaceuticals Ltd SOLID DISPERSION FORMULATIONS AND METHODS OF USE
AR087277A1 (es) * 2011-07-21 2014-03-12 Bristol Myers Squibb Co Composiciones biodisponibles de compuestos amorfos de piperidinilo, composicion farmaceutica, metodos
BR112015015846A2 (pt) 2013-03-07 2017-07-11 Dow Global Technologies Llc éter de celulose esterificado, composição, dispersão sólida, forma de dosagem, invólucro de cápsula e processo para produzir um éter de celulose esterificado
CN105007903B (zh) 2013-03-07 2020-07-17 陶氏环球技术有限责任公司 具有极高分子量的酯化纤维素醚
BR112015019807B1 (pt) 2013-03-07 2020-12-08 Dow Global Technologies Llc acetato succinato de hidroxipropil metilcelulose, composição, dispersão sólida, forma de dosagem e envoltório de cápsula
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
EP2832723B1 (en) * 2013-07-29 2017-02-15 Zentiva, a.s. Stabilised amorphous forms of Saxagliptin
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
EP3212169B1 (en) 2014-10-31 2021-01-13 Bend Research, Inc. Process for forming active domains dispersed in a matrix

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
JPS6314724A (ja) * 1986-07-08 1988-01-21 Tooa Eiyoo Kk プラゾシン製剤
JPH02149518A (ja) * 1988-11-30 1990-06-08 Nikken Chem Co Ltd 経口投与用薬剤
DK546289D0 (da) 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
DE4140185C2 (de) 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4140184C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
US5876754A (en) 1992-01-17 1999-03-02 Alfatec-Pharma Gmbh Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5811547A (en) 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
DE4316537A1 (de) 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
JP3345761B2 (ja) * 1993-06-16 2002-11-18 日本特殊陶業株式会社 ヒーター付スパークプラグ及びその製造方法
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
DE4329446A1 (de) 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
DE19509807A1 (de) 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5685331A (en) 1994-12-20 1997-11-11 Ac & R Components, Inc. Oil level regulator
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
DE19509806A1 (de) 1995-03-21 1996-09-26 Basf Ag Lagerstabile Arzneiformen
DE19509805A1 (de) 1995-03-21 1996-09-26 Basf Ag Transparente, schnell freisetzende Zubereitungen von nichtsteroidalen Analgetica
EP0862420A4 (en) 1995-10-13 1999-11-03 Penn State Res Found SYNTHESIS OF DRUG SPRAY DRUG NANOPARTICLES
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
JPH09309828A (ja) * 1996-03-18 1997-12-02 Eisai Co Ltd 溶解を改善した薬剤組成物
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
JPH107558A (ja) * 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
DE19629753A1 (de) 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
DE19637517A1 (de) 1996-09-13 1998-03-19 Basf Ag Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6403587B1 (en) 1997-02-26 2002-06-11 Pfizer Inc. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-α binding to its CCR 1 receptor
US6126451A (en) 1997-06-02 2000-10-03 Compaq Computer Corporation SCSI connector
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
HN1998000115A (es) 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
SK11262000A3 (sk) 1998-02-05 2001-01-18 Pfizer Products Inc. Deriváty dihydroxyhexánovej kyseliny a farmaceutický prostriedok,ktorý ich obsahuje
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
ATE404178T1 (de) * 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
EP1712222A3 (en) * 1999-12-23 2012-06-20 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
MXPA03011922A (es) 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen un dispersion solida de un farmaco ligeramente soluble en una matriz y plimero mejorador de solubilidad.
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
IL160957A0 (en) 2001-09-28 2004-08-31 Solubest Ltd Water soluble nanoparticles of hydrophilic and hydrophobic active materials
US6848693B2 (en) * 2001-11-20 2005-02-01 Actuant Corporation Pseudo four-leg vehicle leveling system with independent leg lock-out
WO2003063822A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
BRPI0417492A (pt) 2003-12-09 2007-05-29 Pfizer composições compreendendo um inibidor de protease de hiv

Also Published As

Publication number Publication date
EP1530457A1 (en) 2005-05-18
NO20050419L (no) 2005-04-04
ATE442130T1 (de) 2009-09-15
CA2496441A1 (en) 2004-02-19
EP1530457B1 (en) 2009-09-09
IL166411A0 (en) 2006-01-15
CN1681479A (zh) 2005-10-12
US20120322805A1 (en) 2012-12-20
WO2004014342A1 (en) 2004-02-19
GT200300170A (es) 2004-05-12
CA2496441C (en) 2010-03-16
US8491933B2 (en) 2013-07-23
ZA200500470B (en) 2006-07-26
US20040156905A1 (en) 2004-08-12
PE20040865A1 (es) 2004-11-25
PT1530457E (pt) 2009-11-06
PL375345A1 (en) 2005-11-28
US8257739B2 (en) 2012-09-04
EP2111856A3 (en) 2014-09-10
UY27929A1 (es) 2004-03-31
RU2005103625A (ru) 2005-08-20
DE60329188D1 (de) 2009-10-22
TW200406224A (en) 2004-05-01
AU2003249474A1 (en) 2004-02-25
JP2006500349A (ja) 2006-01-05
PA8579801A1 (es) 2004-02-16
EP2111856A2 (en) 2009-10-28
ES2333318T3 (es) 2010-02-19
MXPA05000977A (es) 2005-05-16
BR0313428A (pt) 2005-06-28

Similar Documents

Publication Publication Date Title
AR040969A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
GT200100183A (es) Derivados de quinolina y quinazolina.
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
BRPI0607017B8 (pt) composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
GT200100160A (es) Derivados 4-fenil-piridina.
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
BR0315008A (pt) Compostos neurologicamente ativos
DOP2002000438A (es) Inhibidores de la dipetidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes
IL196767A (en) H1- Amidazo [4,5-b] pyrene-2- (3 h) -one and 1 h- Amidazo [4,5-b] pyrine-2-ol, certain preparations containing them, and the use of compounds in the preparation of a drug
AR033367A1 (es) Derivados de imidazopirimidina y derivados de triazolopirimidina, un procedimiento para su preparacion, medicamentos, una composicion farmaceutica, y uso de dichos derivados para la preparacion de medicamentos
BRPI0713565B8 (pt) processo para fabricação de uma forma de dosagem oral sólida
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
BRPI0520268A2 (pt) recipiente, e, método para produzir um recipiente com aumentada barreira de gás
SV1999000048A (es) Uso de dihidropiriminas como medicamento y nuevas sustancias ref. lea 32 791-sv
AR036813A1 (es) Composiciones farmaceuticas
AR029289A1 (es) Derivado de benzoilpiridina o su sal, fungicida que lo contiene como un ingrediente activo, su proceso de produccion e intermediario para producirlo
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
UY28702A1 (es) Derivados de quinazolina
ECSP066484A (es) Compuestos y metodos para el tratamiento de dislipidemia
BRPI0310032B8 (pt) derivados de benzoxazina, seus usos e seus processos de produção, e composição farmacêutica
BR9913072A (pt) Sistemas de anel azacìclico, composição farmacêutica, e, processo para induzir a analgesia
DE60028367D1 (de) Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten
BR0208405A (pt) Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doenças

Legal Events

Date Code Title Description
FA Abandonment or withdrawal